Avalyn Pharma (NASDAQ:AVLN) Posts Earnings Results, Beats Estimates By $0.05 EPS

Avalyn Pharma (NASDAQ:AVLN) posted its quarterly earnings results on Wednesday. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.05, FiscalAI reports.

Avalyn Pharma Stock Up 5.4%

AVLN stock opened at $37.38 on Thursday. Avalyn Pharma has a fifty-two week low of $24.15 and a fifty-two week high of $39.99. The company has a market cap of $1.66 billion and a PE ratio of -1.71. The stock’s fifty day moving average price is $29.71.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Avalyn Pharma stock. Bank of New York Mellon Corp bought a new stake in shares of Avalyn Pharma Inc. (NASDAQ:AVLN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 40,140 shares of the company’s stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned 0.09% of Avalyn Pharma as of its most recent filing with the Securities and Exchange Commission.

Analysts Set New Price Targets

Several equities analysts have commented on AVLN shares. Zacks Research upgraded shares of Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Evercore assumed coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They set an “outperform” rating and a $51.00 target price for the company. Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $52.00 target price for the company. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Finally, Guggenheim began coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $80.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $59.00.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.